Overview

* ClearPoint Neuro ( CLPT ) Q3 revenue increased 9% yr/yr but missed analyst expectations

* Company announced acquisition of IRRAS Holdings, expanding into neurocritical care

* Neurosurgery navigation and therapy revenue rose 20% driven by Prism Laser Therapy sales

Outlook

* ClearPoint Neuro ( CLPT ) reaffirms 2025 revenue guidance between $36.0 mln and $38.0 mln

* Company expects 2026 combined revenue with IRRAS to be $54.0 mln to $60.0 mln

* Company plans to add 5,000 patient capacity annually for cell and gene therapy trials

Result Drivers

* NEW CUSTOMERS - Activated 5 new global customers in Q3, contributing to revenue growth

* LABORATORY EXPANSION - Opened ClearPoint Advanced Laboratories, increasing capacity for preclinical studies

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $8.90 $9.60

Revenue mln mln (2

Analysts

)

Q3 Gross 63.00%

Margin

Q3 $10.90

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for Clearpoint Neuro Inc ( CLPT ) is $29.00, about 41.4% above its November 5 closing price of $16.98

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)